BELLUS Health Inc. is a clinical biopharmaceutical company that produces therapeutics for refractory chronic cough and cough hypersensitivity indications. Among its product candidates is BLU-5937, which targets the P2X3 receptor and is currently in Phase II clinical trials for RCC and chronic pruritus treatment. Based in Laval, Canada, the company was established in 1993.